DK0577646T3 - Lægemiddelafgivelsesindretning til forlænget afgivelse - Google Patents

Lægemiddelafgivelsesindretning til forlænget afgivelse

Info

Publication number
DK0577646T3
DK0577646T3 DK92906830T DK92906830T DK0577646T3 DK 0577646 T3 DK0577646 T3 DK 0577646T3 DK 92906830 T DK92906830 T DK 92906830T DK 92906830 T DK92906830 T DK 92906830T DK 0577646 T3 DK0577646 T3 DK 0577646T3
Authority
DK
Denmark
Prior art keywords
coating layer
effective agent
inner core
drug delivery
release drug
Prior art date
Application number
DK92906830T
Other languages
Danish (da)
English (en)
Inventor
Thomas J Smith
Paul Ashton
Paul A Pearson
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Application granted granted Critical
Publication of DK0577646T3 publication Critical patent/DK0577646T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
DK92906830T 1991-02-21 1992-02-21 Lægemiddelafgivelsesindretning til forlænget afgivelse DK0577646T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/658,695 US5378475A (en) 1991-02-21 1991-02-21 Sustained release drug delivery devices
PCT/US1992/001432 WO1992014450A1 (fr) 1991-02-21 1992-02-21 Systemes d'administration de medicaments a liberation prolongee

Publications (1)

Publication Number Publication Date
DK0577646T3 true DK0577646T3 (da) 1999-06-21

Family

ID=24642282

Family Applications (2)

Application Number Title Priority Date Filing Date
DK92906830T DK0577646T3 (da) 1991-02-21 1992-02-21 Lægemiddelafgivelsesindretning til forlænget afgivelse
DK98104053.8T DK0861659T3 (da) 1991-02-21 1992-02-21 Indretninger til administration af lægemidler med forsinket frigivelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98104053.8T DK0861659T3 (da) 1991-02-21 1992-02-21 Indretninger til administration af lægemidler med forsinket frigivelse

Country Status (10)

Country Link
US (1) US5378475A (fr)
EP (2) EP0577646B1 (fr)
JP (2) JPH06505274A (fr)
AT (2) ATE171617T1 (fr)
AU (1) AU660012B2 (fr)
CA (1) CA2104699C (fr)
DE (1) DE69227187T2 (fr)
DK (2) DK0577646T3 (fr)
ES (2) ES2125259T3 (fr)
WO (1) WO1992014450A1 (fr)

Families Citing this family (442)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
IL100112A (en) * 1991-11-21 1996-01-31 Yeda Res & Dev Microdelivery device for enhanced drug administration to the eye
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5876438A (en) * 1993-08-02 1999-03-02 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5928662A (en) * 1996-07-31 1999-07-27 Phillips; Andrew F. Ocular drug delivery device
EP0973499B1 (fr) * 1997-03-31 2003-08-06 Alza Corporation Systeme d'administration par diffusion, implantable
US20040009924A1 (en) * 1997-05-30 2004-01-15 Veronique Stoven Anticancer products for treating cystic fibrosis
EP1001743B1 (fr) * 1997-06-04 2006-02-01 Debio Recherche Pharmaceutique S.A. Implants pour la liberation controlee de principes pharmaceutiquement actifs et procede pour leur fabrication
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6210639B1 (en) 1998-10-26 2001-04-03 Novartis Ag Apparatus, method and composition for cleaning and disinfecting
ATE404172T1 (de) 1998-12-30 2008-08-15 Dexcel Ltd Dispergierbares konzentrat zur verabreichung von cyclosporin
CA2358296A1 (fr) * 1999-01-05 2000-07-13 Anthony P. Adamis Administration ciblee de medicament a liberation regulee vers la retine et la choroide a travers la sclerotique
DE60017363T2 (de) 1999-02-02 2006-03-02 Wright Medical Technology Inc., Arlington Kontrollierte freisetzung eines verbundmaterials
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6413245B1 (en) 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AU768400B2 (en) * 1999-10-21 2003-12-11 Alcon Inc. Drug delivery device
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
EP1241973B1 (fr) 1999-12-28 2007-04-11 Kimberly-Clark Worldwide, Inc. Systeme indicateur dependant de l'utilisation pour des articles absorbants
WO2001047705A1 (fr) 1999-12-28 2001-07-05 Kimberly-Clark Worldwide, Inc. Chiffon antimicrobien a liberation controlee pour surfaces dures
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ATE547080T1 (de) * 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
US9925087B2 (en) * 2000-09-15 2018-03-27 Bruder Healthcare Company, Llc Wound and therapy compress and dressing
ATE343969T1 (de) * 2000-09-29 2006-11-15 Cordis Corp Beschichtete medizinische geräte
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
WO2002056863A2 (fr) * 2000-12-29 2002-07-25 Bausch & Lomb Incorporated Dispositif d'apport de medicaments en continu
ES2320533T3 (es) 2001-01-03 2009-05-25 BAUSCH & LOMB INCORPORATED Dispositivos de administracion de farmacos de liberacion sostenida con multiples agentes.
EP1847255A3 (fr) * 2001-01-03 2009-03-04 Bausch & Lomb Incorporated Dispositifs de livraison de médicaments à libération prolongée avec noyaux de médicaments recouverts
ES2294043T3 (es) * 2001-01-03 2008-04-01 BAUSCH & LOMB INCORPORATED Dispositivos de liberacion prolongada de medicamentos que comprenden nucleos recubiertos de medicamentos.
CA2432225C (fr) * 2001-01-03 2008-01-15 Michael J. Brubaker Dispositifs d'administration de medicament a liberation prolongee a tampons permeables prefabriques
US6991808B2 (en) * 2001-01-26 2006-01-31 Bausch & Lomb Inc. Process for the production of sustained release drug delivery devices
US7181287B2 (en) * 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
EP1387671A1 (fr) 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Dispositif d'administration de medicament implantable et utilisation associee
EP2316394B1 (fr) 2001-06-12 2016-11-23 The Johns Hopkins University Dispositif à réservoir pour administration intraoculaire de médicaments
DE10133870A1 (de) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmisches Mittel, Verwendung von EGF zur Behandlung von Dry Eye-Syndrom und Insert zur Verabreichung von EGF am Auge
PT1385452E (pt) * 2001-07-23 2006-12-29 Alcon Inc Dispositivo de administração de fármacos oftálmicos
PT1409065E (pt) 2001-07-23 2007-03-30 Alcon Inc Dispositivo de administração de fármacos oftálmicos
US20030158598A1 (en) * 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7217381B2 (en) 2001-09-28 2007-05-15 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US20040062804A1 (en) * 2001-09-28 2004-04-01 Der-Yang Lee Modified release dosage forms
US6982094B2 (en) 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US20060034929A1 (en) * 2001-12-27 2006-02-16 Brubaker Michael J Sustained release drug delivery devices with prefabricated permeable plugs
US8685427B2 (en) * 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
AU2003216379A1 (en) * 2002-02-22 2003-09-09 Control Delivery Systems, Inc. Method for treating otic disorders
EP2522319A3 (fr) * 2002-03-11 2013-09-25 Novartis AG Système de distribution de médicament implantable
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
WO2003094888A1 (fr) * 2002-05-07 2003-11-20 Control Delivery Systems, Inc. Procedes de fabrication d'un distributeur de medicaments
NZ536308A (en) * 2002-05-24 2009-01-31 Angiotech Int Ag Compositions and methods for coating medical implants
US8313760B2 (en) * 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US20030235610A1 (en) * 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
US6976584B2 (en) * 2002-06-26 2005-12-20 Bausch & Lomb Incorporated Package for surgical implant
CN100435880C (zh) * 2003-02-28 2008-11-26 微创医疗器械(上海)有限公司 一种药物洗脱介入医疗器械及其制备方法
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
BR0312635A (pt) * 2002-07-15 2005-04-19 Alcon Inc Composições de implante farmacêutico lipofìlico não polimérico para uso intraocular
US8920826B2 (en) * 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
DE10238310A1 (de) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh Elektrodenanordnung
ES2428354T3 (es) * 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
US6899717B2 (en) * 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US20050203542A1 (en) * 2002-09-18 2005-09-15 Allergan, Inc. Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events
KR20050047118A (ko) * 2002-09-18 2005-05-19 알러간, 인코포레이티드 안과 임플란트의 수송을 위한 방법 및 장치
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
CA2689424A1 (fr) * 2002-09-29 2004-04-08 Surmodics, Inc. Methodes pour le traitement et/ou la prevention de maladies de la retine
WO2004036182A2 (fr) * 2002-10-17 2004-04-29 Control Delivery Systems, Inc. Procede de suivi de traitement de maladie
AU2003287666A1 (en) * 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
JP2006521287A (ja) 2002-12-20 2006-09-21 エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ 医薬製剤用の高圧圧縮
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
WO2004066980A2 (fr) * 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Dispositif et procede a liberation prolongee pour l'administration oculaire d'inhibiteurs d'anhydrase carbonique
CN1741793A (zh) * 2003-01-24 2006-03-01 控释给药系统公司 高可溶性药物的控制释放
SI1592408T1 (sl) * 2003-01-24 2010-01-29 Psivida Inc Naprava s podaljšanim sproščanjem in postopek za okularno dajanje adrenergičnih sredstev
WO2004073551A2 (fr) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Dispositif d'administration transsclerale de medicament et procedes associes
CA2516790A1 (fr) * 2003-02-20 2004-09-02 Alcon, Inc. Preparations de glucocorticoides pour le traitement de l'angiogenese oculaire pathologique
BRPI0407693A (pt) * 2003-02-20 2006-03-01 Alcon Inc uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US9445901B2 (en) * 2003-03-12 2016-09-20 Deger C. Tunc Prosthesis with sustained release analgesic
US7483750B2 (en) * 2003-03-21 2009-01-27 Second Sight Medical Products, Inc. Transretinal implant and method of implantation
US7037521B2 (en) * 2003-03-28 2006-05-02 Bausch & Lomb Incorporated Using a laser for cutting a hole in a capsule for controlled drug delivery
US20050261668A1 (en) * 2003-03-28 2005-11-24 Bausch & Lomb Incorporated Drug delivery device
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
JP4824549B2 (ja) * 2003-05-02 2011-11-30 サーモディクス，インコーポレイティド 制御放出型の生体活性物質デリバリー・デバイス
US7589107B2 (en) * 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
EP1633339A4 (fr) * 2003-06-13 2009-06-03 Alcon Inc Preparation d'agents anti-inflammatoires non steroidiens pour traiter l'angiogenese oculaire pathologique
CA2527805C (fr) 2003-06-16 2012-08-21 Institute Of Organic Chemistry And Biochemistry, Academy Of Sciences Of The Czech Republic Composes de pyrimidine a groupes phosphonate, en tant qu'analogues nucleotidiques antiviraux
JP5628467B2 (ja) * 2003-06-26 2014-11-19 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 生体分解性徐放性ドラッグデリバリーシステム
TWI377958B (en) 2003-06-26 2012-12-01 Control Delivery Sys Inc In-situ gelling drug delivery system
CN1842321B (zh) * 2003-06-26 2012-07-04 控制递送系统有限公司 生物蚀解性缓释递药系统
US20040265356A1 (en) * 2003-06-30 2004-12-30 Bausch & Lomb Incorporated Drug delivery device
US20050054586A1 (en) * 2003-06-30 2005-03-10 Bartels Stephen P. Treatment of ophthalmic disorders
CN1805719A (zh) * 2003-07-10 2006-07-19 爱尔康公司 眼药输送装置
WO2005012537A2 (fr) * 2003-07-25 2005-02-10 Genvec, Inc. Vaccins a base de vecteurs adenoviraux
CA2539324A1 (fr) * 2003-09-18 2005-03-31 Macusight, Inc. Administration transsclerale d'agents therapeutiques
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
DK1696822T3 (da) * 2003-11-13 2010-05-17 Psivida Inc Injicerbart vedvarende frigørelsesimplantat, som har en bioeroderbar matrixkerne og en bioeroderbar hus
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
AU2004293463A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
US20050130906A1 (en) * 2003-11-20 2005-06-16 Matier William L. Amelioration of macular degeneration and other ophthalmic diseases
BRPI0405798B8 (pt) * 2003-11-28 2021-05-25 Halex Istar Ind Farmaceutica L processo de eliminação de resíduos alcalinos presentes no 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amino-1h-purin-6(9h)-ona e apresentação farmacêutica
US7211272B2 (en) * 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
US20050137538A1 (en) 2003-12-22 2005-06-23 Bausch & Lomb Incorporated Drug delivery device
US20050158365A1 (en) 2003-12-22 2005-07-21 David Watson Drug delivery device with mechanical locking mechanism
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
JP2007518804A (ja) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
CN101018541A (zh) * 2004-01-26 2007-08-15 普西维达公司 核酸基治疗药剂的受控和持续传输
US20060018949A1 (en) * 2004-04-07 2006-01-26 Bausch & Lomb Incorporated Injectable biodegradable drug delivery system
CN1972958B (zh) 2004-04-12 2013-01-23 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
WO2005102334A2 (fr) * 2004-04-13 2005-11-03 Alza Corporation Appareil et procede d'administration transdermique d'agents a base de fentanyle
US7691381B2 (en) 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
WO2005107708A1 (fr) 2004-04-30 2005-11-17 Allergan, Inc. Implants d'inhibiteurs de tyrosine kinase intravitreens, biodegradables
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
CA2572223C (fr) 2004-06-25 2014-08-12 The Johns Hopkins University Inhibiteurs d'angiogenese
EP3470108A1 (fr) * 2004-07-02 2019-04-17 Mati Therapeutics Inc. Dispositif de mise en place d'un moyen de traitement destinees a la mise en place dans l'oeil
EP1611879B1 (fr) * 2004-07-02 2009-08-12 Novagali Pharma SA Utilisation des émulsions pour injection intra- et périoculaire.
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
JP2008505978A (ja) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド 眼病用組成物および眼病治療法
AU2005274948B2 (en) 2004-07-16 2011-09-22 Genvec, Inc. Vaccines against aids comprising CMV/R-nucleic acid constructs
AU2005269599A1 (en) * 2004-07-26 2006-02-09 Clarity Corporation Implantable device having reservoir with controlled release of medication and method of manufacturing the same
US20060020253A1 (en) * 2004-07-26 2006-01-26 Prescott Anthony D Implantable device having reservoir with controlled release of medication and method of manufacturing the same
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
WO2006023130A2 (fr) * 2004-08-12 2006-03-02 Surmodics, Inc. Dispositif biodegradable de diffusion d'un agent bioactif a liberation lente
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006026504A2 (fr) * 2004-08-27 2006-03-09 Spherics, Inc. Formulations orales mucoadhesives de medicaments a permeabilite et solubilite elevees
JP2008511336A (ja) * 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US20060116404A1 (en) 2004-09-24 2006-06-01 Gary Robinson CAI-based systems and methods for the localized treatment of ocular and other diseases
US20060067978A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly(vinyl alcohol) drug delivery devices
US20060068012A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control
US20060067980A1 (en) * 2004-09-30 2006-03-30 Bausch & Lomb Incorporated Capsule for encasing tablets for surgical insertion into the human body
US20060067979A1 (en) * 2004-09-30 2006-03-30 Bausch & Lomb Incorporated Ophthalmic drug release device for multiple drug release
US20060078592A1 (en) * 2004-10-12 2006-04-13 Bausch & Lomb Incorporated Drug delivery systems
US20070276481A1 (en) * 2004-12-08 2007-11-29 Renner Steven B Drug delivery device
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
WO2006068921A2 (fr) * 2004-12-22 2006-06-29 Alcon, Inc. Dispositif d'administration d'un medicament ophtalmique
WO2006068898A1 (fr) * 2004-12-22 2006-06-29 Bausch & Lomb Incorporated Dispositif de distribution de medicament reutilisable
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
JP2008535847A (ja) * 2005-04-08 2008-09-04 サーモディクス，インコーポレイティド 網膜下に送達するための持続放出インプラント
US20080312283A1 (en) * 2005-05-26 2008-12-18 Othera Pharmaceuticals, Inc. Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
US20060292222A1 (en) * 2005-06-21 2006-12-28 Matthew Jonasse Drug delivery device having zero or near zero-order release kinetics
US20060292202A1 (en) * 2005-06-27 2006-12-28 Bausch & Lomb Incorporated Drug delivery device
WO2007014327A2 (fr) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Petits composes corrigeant un mauvais repliement des proteines et utilisations de ceux-ci
AU2006284756B2 (en) * 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
EP1937244B1 (fr) 2005-09-30 2018-07-25 Io Therapeutics, LLC Traitement du cancer a l'aide d'agonistes de rxr specifiques
WO2007047626A1 (fr) * 2005-10-14 2007-04-26 Alcon, Inc. Traitement de combinaison comprenant de l'acetate d'anecortave et du bevacizumab ou du ranibizumab pour une angiogenese oculaire pathologique
EP1956906A4 (fr) 2005-11-09 2009-12-30 Combinatorx Inc Procedes, compositions et kits pour le traitement de pathologies
CA2629163C (fr) * 2005-11-10 2017-03-21 Genvec, Inc. Vaccin contre la fievre aphteuse a base de vecteur adenoviral
US20070122449A1 (en) * 2005-11-28 2007-05-31 Choonara Yahya E Biodegradable implantable drug delivery device
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
US20110034498A1 (en) * 2006-03-24 2011-02-10 Mcgovern Karen J Dosing regimens for the treatment of cancer
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7981096B2 (en) * 2006-05-12 2011-07-19 David Castillejos Optic nerve head implant and medication delivery system
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
BRPI0714815A2 (pt) 2006-08-07 2013-05-21 Bausch & Lomb composiÇço, e, uso de um (a) agonista e (b) um agente anti-infeccioso
EP2056833A2 (fr) 2006-08-23 2009-05-13 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Procédé de traitement ou de prévention d'une maladie associée au stress oxydatif
CN101528208A (zh) * 2006-08-31 2009-09-09 博士伦公司 治疗或预防青光眼或其进展的组合物和方法
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20110104159A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
KR20090050076A (ko) * 2006-09-11 2009-05-19 보오슈 앤드 롬 인코포레이팃드 알레르기를 치료, 관리, 경감, 개선 또는 예방하기 위한 조성물 및 방법
US20110105559A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
EP1973528B1 (fr) 2006-11-17 2012-11-07 Supernus Pharmaceuticals, Inc. Formulations de topiramate à libération prolongée
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US20080145405A1 (en) * 2006-12-15 2008-06-19 Kunzler Jay F Drug delivery devices
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008086386A2 (fr) * 2007-01-09 2008-07-17 Genvec, Inc. Vaccins antipaludéens à base de vecteur adénoviral
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
US8622991B2 (en) * 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
EP2136863A2 (fr) * 2007-03-19 2009-12-30 Insuline Medical Ltd. Dispositif d'administration de médicament et connexions associées à celui-ci
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
CN101678169A (zh) * 2007-03-19 2010-03-24 茵苏莱恩医药有限公司 药物输送设备
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
US7910123B2 (en) * 2007-09-05 2011-03-22 Warsaw Orthopedic Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent
US20090062922A1 (en) * 2007-09-05 2009-03-05 Mckay William F Method and apparatus for delivering treatment to a joint
US20090104243A1 (en) * 2007-09-07 2009-04-23 Qlt Plug Delivery, Inc. - Qpdi Drug cores for sustained release of therapeutic agents
US20090087443A1 (en) 2007-09-27 2009-04-02 Bartels Stephen P Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
TWI451862B (zh) * 2007-10-09 2014-09-11 Alcon Res Ltd 用於眼睛注射的熱係數驅動藥丸尺寸
TWI498136B (zh) * 2007-10-09 2015-09-01 Alcon Res Ltd 用於遞送速率及溫度相依性物質至眼睛的注射器及其製備方法
US9849027B2 (en) * 2007-11-08 2017-12-26 Alimera Sciences, Inc. Ocular implantation device
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
US8409133B2 (en) 2007-12-18 2013-04-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
EP3190121B1 (fr) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Procédés de réduction stéréo-sélective du derivé 4-en-3-one de cyclopamine
JP2011522773A (ja) * 2007-12-27 2011-08-04 インフィニティ ファーマスーティカルズ、インク． 治療剤での癌の処置方法
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US8173163B2 (en) 2008-02-21 2012-05-08 Rutgers, The State University Of New Jersey Polymeric drug delivery compositions and methods for treating ophthalmic diseases
US20100152646A1 (en) * 2008-02-29 2010-06-17 Reshma Girijavallabhan Intravitreal injection device and method
WO2009140246A2 (fr) 2008-05-12 2009-11-19 University Of Utah Research Foundation Dispositif d'administration intraoculaire de médicament et procédés associés
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
WO2010024930A2 (fr) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Analogues de cortistatine et leurs synthèses
US7985208B2 (en) * 2008-09-18 2011-07-26 Oasis Research LLC Ring shaped contoured collagen shield for ophthalmic drug delivery
WO2010052579A2 (fr) 2008-11-07 2010-05-14 Insuline Medical Ltd. Dispositif et méthode d’administration de médicament
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
WO2010093945A2 (fr) 2009-02-13 2010-08-19 Glaukos Corporation Implant médicamenteux uvéoscléral et ses procédés d'implantation
WO2010096561A1 (fr) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines gag du vih/vis de synthèse et leurs utilisations
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US8372036B2 (en) * 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
AU2010249683B2 (en) * 2009-05-18 2015-06-25 Dose Medical Corporation Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2012071476A2 (fr) 2010-11-24 2012-05-31 David Haffner Implant oculaire à élution de médicament
CA2764063C (fr) 2009-06-03 2019-05-14 Forsight Labs, Llc Distribution de medicament de segment anterieur
IN2012DN00352A (fr) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (fr) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccins à base de vecteur adénoviral simien
CN102724951A (zh) 2009-11-09 2012-10-10 阿勒根公司 用于刺激毛发生长的组合物和方法
US9205091B2 (en) 2009-11-13 2015-12-08 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
US8177747B2 (en) * 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US20110238036A1 (en) * 2009-12-23 2011-09-29 Psivida Us, Inc. Sustained release delivery devices
WO2011088404A1 (fr) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Traitement de pathologies fibrotiques à l'aide d'inhibiteurs de la voie hedgehog
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
AU2011213616B2 (en) 2010-02-08 2013-08-15 Microchips, Inc. Low-permeability, laser-activated drug delivery device
KR101876693B1 (ko) 2010-03-08 2018-07-09 스펙트럼 파마슈티컬즈 인크 암을 치료하기 위한 티옥산톤계 자가포식작용 저해제 치료제
US9682133B2 (en) 2010-03-17 2017-06-20 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
EP2547660B1 (fr) 2010-03-19 2015-01-07 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Composés libérant du nitroxyle (hno) et leurs utilisations dans le traitement de maladies
EP2383286A1 (fr) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pour le traitement des maladies rétiniennes dégénératives
CA2798084A1 (fr) 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Dispositifs d'administration de medicament pour administration d'agents therapeutiques oculaires
WO2011159824A1 (fr) 2010-06-16 2011-12-22 Allergan, Inc. Composition et méthode de traitement d'une vessie hyperactive
SI2600930T1 (sl) 2010-08-05 2021-08-31 Forsight Vision4, Inc. Injekcijska naprava za dajanje zdravila
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
HUE057267T2 (hu) 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
WO2012021730A2 (fr) 2010-08-11 2012-02-16 Genvec, Inc. Vaccin contre le virus syncytial respiratoire (vsr)
US8697056B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
WO2012037217A1 (fr) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Hydrogénation par transfert d'analogues de cyclopamine
WO2012068549A2 (fr) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Formulations d'agents thérapeutiques pour des dispositifs implantés
WO2012083297A2 (fr) 2010-12-17 2012-06-21 Genvec, Inc. Vecteurs adénoviraux avec régions d'hexon modifiées
EP2654786B1 (fr) 2010-12-20 2019-02-20 GenVec, Inc. Vaccin contre la dengue à base d'un vecteur adénoviral
US20120238994A1 (en) * 2010-12-22 2012-09-20 Martin Nazzaro Two-piece injectable drug delivery device with heat-cured seal
WO2012112757A2 (fr) 2011-02-17 2012-08-23 Allergan, Inc. Compositions et procédés améliorés de remplacement de tissu mou
EP2678022A2 (fr) 2011-02-23 2014-01-01 Allergan, Inc. Compositions et procédés de remplacement de tissu mou améliorés
US9012647B2 (en) 2011-04-07 2015-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders
US8889672B2 (en) 2011-04-29 2014-11-18 The Regents Of The University Of Michigan Compounds, formulations, and methods of protein kinase C inhibition
SG194843A1 (en) 2011-05-18 2013-12-30 Univ California Compositions and methods for treating retinal diseases
WO2012162428A1 (fr) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Primovaccination-rappel pour infection virale
WO2012170578A1 (fr) * 2011-06-06 2012-12-13 Oak Crest Institute Of Science Dispositif d'administration de médicament employant une fenêtre de libération par inhibition par capillarité
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US20120316199A1 (en) 2011-06-07 2012-12-13 Ward Keith W Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
BR112013032199A2 (pt) 2011-06-14 2017-12-12 Bikam Pharmaceuticals Inc ligantes de ligação à opsina, composições e métodos de utilização
EP2726016B1 (fr) 2011-06-28 2023-07-19 ForSight Vision4, Inc. Un appareil pour collecter un échantillon de fluide à partir d'une chambre réservoir d'un dispositif thérapeutique pour l'oeil
EP2741720A1 (fr) 2011-08-10 2014-06-18 On Demand Therapeutics, Inc. Dispositif d'administration de médicament activé par laser
WO2013040238A2 (fr) 2011-09-13 2013-03-21 Vista Scientific Llc Dispositifs d'administration de médicaments oculaires à libération prolongée et procédés de fabrication correspondants
CN106073986B (zh) * 2011-09-14 2019-01-11 弗赛特影像5股份有限公司 治疗患者的眼睛的装置
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US8685106B2 (en) 2011-11-15 2014-04-01 Abraham Lin Method of a pharmaceutical delivery system for use within a joint replacement
US9353063B2 (en) 2011-11-30 2016-05-31 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP6322142B2 (ja) 2011-12-01 2018-05-09 ビカム ファーマスーティカルス，インコーポレイテッド オプシン結合性リガンド、組成物、及び使用方法
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
AU2012352149B2 (en) 2011-12-13 2017-06-01 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US10080648B2 (en) 2012-01-24 2018-09-25 Clarvista Medical, Inc. Modular intraocular lens designs, tools and methods
US10028824B2 (en) 2012-01-24 2018-07-24 Clarvista Medical, Inc. Modular intraocular lens designs, tools and methods
US9364316B1 (en) * 2012-01-24 2016-06-14 Clarvista Medical, Inc. Modular intraocular lens designs, tools and methods
JP6270739B2 (ja) 2012-01-24 2018-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド, ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate モジュール式眼内レンズの設計および方法
WO2013116061A1 (fr) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Procédés et instrument pour l'insertion et le retrait de dispositifs thérapeutiques
EP2811952A1 (fr) 2012-02-07 2014-12-17 On Demand Therapeutics, Inc. Dispositifs d'administration de médicament et leurs procédés d'utilisation
WO2013123275A1 (fr) 2012-02-16 2013-08-22 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
EP2814482A1 (fr) 2012-02-16 2014-12-24 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
EP2814510A1 (fr) 2012-02-16 2014-12-24 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
WO2013123274A1 (fr) 2012-02-16 2013-08-22 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
US20150038557A1 (en) 2012-02-24 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treatment of retinal degenerative diseases
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US10004811B2 (en) 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
EP2855030B1 (fr) 2012-06-01 2019-08-21 SurModics, Inc. Appareil et méthode de revêtement de cathéters à ballonnet
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
NZ706067A (en) 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
CA2887893C (fr) 2012-10-09 2021-07-06 Douglas SEARS Traitement therapeutique du trouble deficitaire de l'attention
AU2013336683A1 (en) 2012-10-24 2015-05-14 Biocopea Limited Drug combinations containing statins for treating cardiovascular diseases
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2014066775A1 (fr) 2012-10-26 2014-05-01 Forsight Vision5, Inc. Système ophtalmique pour la libération prolongée de médicament dans l'œil
WO2014093270A1 (fr) 2012-12-10 2014-06-19 Virginia Commonwealth University Virus terminateur de cancer à tropisme modifié (ad.5/3 ctv ; ad.5/3-ctv-m7)
JP6513576B2 (ja) 2013-01-14 2019-05-15 ヘルス クリニックス リミテッド 抗がん剤および使用
EP2956096A1 (fr) 2013-02-15 2015-12-23 Allergan, Inc. Implant à administration de médicament prolongée
WO2014164703A1 (fr) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Délivrance d'une protéine card en tant que thérapie pour inflammation oculaire
WO2014152959A1 (fr) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systèmes pour l'administration intra-oculaire entretenue de composés à faible solubilité provenant d'un implant de système de pose d'orifice
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
AU2014235854B2 (en) 2013-03-21 2019-04-11 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
EP4302736A3 (fr) 2013-03-28 2024-04-03 ForSight Vision4, Inc. Implant ophtalmique pour l'administration de substances thérapeutiques
JP6340673B2 (ja) 2013-05-02 2018-06-13 レティナ ファウンデーション オブ ザ サウスウエストＲｅｔｉｎａ Ｆｏｕｎｄａｔｉｏｎ Ｏｆ Ｔｈｅ Ｓｏｕｔｈｗｅｓｔ 二層型眼用インプラント
US20160355573A1 (en) 2013-09-05 2016-12-08 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
US10087224B2 (en) 2013-11-01 2018-10-02 Cornell University Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions
EA201891279A1 (ru) 2013-12-24 2019-01-31 Президент Энд Феллоус Оф Гарвард Колледж Аналоги кортистатина, их синтез и применения
WO2015112739A1 (fr) 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composés et méthode de traitement de cancers à déficit en parp1
EP4215159A1 (fr) 2014-02-18 2023-07-26 Alcon Inc. Conceptions de lentille intraoculaire modulaire, outils et procédés associés
WO2015184173A1 (fr) 2014-05-29 2015-12-03 Dose Medical Corporation Implants à caractéristiques de libération contrôlée de médicament et leurs procédés d'utilisation
US20160008376A1 (en) 2014-07-10 2016-01-14 Biocopea Limited Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
KR102416726B1 (ko) 2014-07-15 2022-07-05 포사이트 비젼4, 인크. 안구 이식물 전달 디바이스 및 방법
WO2016022750A1 (fr) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Formulations stables et solubles d'inhibiteurs de la tyrosine kinase de récepteurs, et procédés de préparation de ces dernières
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
JP7002331B2 (ja) 2015-01-30 2022-01-20 クラービスタ メディカル，インコーポレイテッド 眼内挿入用に構成された装置
WO2016164920A1 (fr) 2015-04-09 2016-10-13 Cornell University Thérapie génique pour prévenir les réactions à des allergènes
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
EP3294298A4 (fr) 2015-05-08 2018-10-17 President and Fellows of Harvard College Analogues de la cortistatine, synthèses, et utilisations de ces derniers
EP3294894B8 (fr) 2015-05-12 2019-09-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Isolat de virus adéno-associé et protéine de fusion comprenant un peptide signal du facteur de croissance des nerfs et l'hormone parathyroïdienne
KR20180014051A (ko) 2015-05-28 2018-02-07 코넬 유니버시티 혈관 부종 치료제로서의 아데노-관련 바이러스 매개 c1e1의 전달
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
US10206978B2 (en) 2015-06-08 2019-02-19 Retinal Solutions Llc Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema
US10202429B2 (en) 2015-06-08 2019-02-12 Retinal Solutions Llc Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema
US10669321B2 (en) 2015-06-08 2020-06-02 Retinal Solutions Llc Retinal capillary regeneration with synthetic norrin protein
WO2017004411A1 (fr) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Analogues de la cortistatine, et synthèses et leurs utilisations
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
ES2672993T3 (es) 2015-10-27 2018-06-19 Eupraxia Pharmaceuticals Inc. Formulaciones de liberación sostenida de anestésicos locales
NZ741393A (en) 2015-10-31 2018-11-30 Io Therapeutics Inc Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
AU2016349363B2 (en) 2015-11-04 2022-01-27 Alcon Inc. Modular intraocular lens designs, tools and methods
US11180538B2 (en) 2015-11-13 2021-11-23 University Of Utah Research Foundation Combinatorial gene construct and non-viral delivery for anti-obesity
AU2016355345A1 (en) 2015-11-20 2018-05-31 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
CA3014774A1 (fr) 2016-02-17 2017-08-24 Children's Medical Center Corporation Ffa1 (gpr40) utilise comme cible therapeutique pour des maladies ou des troubles neuronaux lies a l'angiogenese
US12029681B2 (en) 2016-03-01 2024-07-09 The Hilsinger Company Parent, Llc Therapeutic eye mask system
US12011388B2 (en) 2016-03-01 2024-06-18 The Hilsinger Company Parent, Llc Therapeutic thermal compress with phase-change material
WO2017155578A1 (fr) 2016-03-10 2017-09-14 Io Therapeutics, Inc. Traitement de troubles musculaires avec des combinaisons d'agonistes de rxr et d'hormones thyroïdiennes
EP3426302B1 (fr) 2016-03-10 2022-12-14 IO Therapeutics, Inc. Traitement de maladies auto-immunes à l'aide de combinaisons d'agonistes de rxr et d'hormones thyroïdiennes
CN109195556B (zh) 2016-04-05 2021-03-26 弗赛特影像4股份有限公司 可植入眼睛药物递送装置
CN109937025B (zh) 2016-04-20 2022-07-29 多斯医学公司 生物可吸收眼部药物的递送装置
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
US11045309B2 (en) 2016-05-05 2021-06-29 The Regents Of The University Of Colorado Intraocular lens designs for improved stability
USD844795S1 (en) 2016-11-30 2019-04-02 Bruder Healthcare Company, Llc Therapeutic eye mask
USD871598S1 (en) 2016-11-30 2019-12-31 Bruder Healthcare Company, Llc Therapeutic eye mask
US11406533B2 (en) 2017-03-17 2022-08-09 W. L. Gore & Associates, Inc. Integrated aqueous shunt for glaucoma treatment
TW201920654A (zh) 2017-06-05 2019-06-01 加州大學董事會 用來治療視網膜疾病的組合物及其製造與使用方法
US11382736B2 (en) 2017-06-27 2022-07-12 Alcon Inc. Injector, intraocular lens system, and related methods
US11103460B2 (en) 2017-08-07 2021-08-31 Board Of Regents, The University Of Texas System Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
CA3076373A1 (fr) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Traitement de maladie avec des esters d'agonistes de rxr selectifs
CA3077189A1 (fr) 2017-10-02 2019-04-11 Genedit Inc. Arn guide cpf1 modifie
EP3697401A4 (fr) 2017-10-18 2021-11-24 Washington University Molécules sarm1 négatives dominantes en tant que stratégie thérapeutique pour des maladies ou des troubles neurodégénératifs
WO2019103906A1 (fr) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Appareil d'échange de fluide pour système d'administration à port extensible et méthodes d'utilisation
KR20240132386A (ko) 2017-12-29 2024-09-03 코넬 유니버시티 호산구성 장애에 대한 유전자 요법
EP3775177A1 (fr) 2018-04-03 2021-02-17 Cornell University Thérapie génique contre le stress oxydatif
WO2019222121A1 (fr) * 2018-05-12 2019-11-21 Goldenbiotech, Llc Dispositif d'administration de médicament implantable à retenue automatique
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
CN111971026A (zh) 2018-05-24 2020-11-20 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
AU2019275409B2 (en) 2018-05-24 2024-08-15 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
EP3829718A4 (fr) 2018-07-31 2022-06-22 Cornell University Procédés de thérapie génique pour contrôler la fonction d'un organe
WO2020112816A1 (fr) 2018-11-29 2020-06-04 Surmodics, Inc. Appareil et méthodes de revêtement de dispositifs médicaux
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
US11039954B2 (en) 2019-03-21 2021-06-22 Microoptx Inc. Implantable ocular drug delivery devices and methods
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
BR112021026265A2 (pt) 2019-06-27 2022-06-14 Layerbio Inc Métodos e sistemas de entrega de dispositivos oculares
EP4007609A1 (fr) 2019-08-01 2022-06-08 Cornell University Thérapie génique ciblée pour traiter des maladies neurologiques
WO2021067550A1 (fr) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Procédés et compositions pour identifier des néo-antigènes destinés à être utilisés dans le traitement et la prévention du cancer
WO2021076794A1 (fr) 2019-10-15 2021-04-22 Cornell University Procédés de modulation du niveau d'expression à partir d'une cassette d'expression de thérapie génique
US20230405148A1 (en) 2019-10-16 2023-12-21 Cornell University Gene therapy for alzheimer's disease
WO2021086973A2 (fr) 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation pour l'administration d'un gène de lubricine
KR20220107243A (ko) 2019-11-25 2022-08-02 코넬 유니버시티 Apoe 유전자 요법
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
US11826421B2 (en) 2020-03-20 2023-11-28 Athanor Biosciences, Inc. Bacteriophage-based vaccines and engineered bacteriophage
WO2021207069A1 (fr) 2020-04-05 2021-10-14 Athanor Biosciences, Inc. Anticorps à base de bactériophages et liants à base de protéines
EP4138921A1 (fr) 2020-04-23 2023-03-01 University Of Iowa Research Foundation Chimères de ciblage protéolytique gper
EP4157309A1 (fr) 2020-06-01 2023-04-05 Black Cat Bio Limited Compositions et méthodes de traitement d'infections et de nétopathies
WO2022011099A1 (fr) 2020-07-08 2022-01-13 Regents Of The University Of Minnesota Hexosaminidase modifiée et ses utilisations
WO2022036104A1 (fr) 2020-08-12 2022-02-17 University Of Iowa Research Foundation Sensibilisateurs à l'insuline pour le traitement du diabète sucré
WO2022040564A1 (fr) 2020-08-21 2022-02-24 University Of Iowa Research Foundation Adjuvants de nanoparticules cationiques
US20230414787A1 (en) 2020-08-27 2023-12-28 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
US20240100183A1 (en) 2020-12-11 2024-03-28 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
EP4340894A1 (fr) 2021-05-21 2024-03-27 University Of Iowa Research Foundation Particules contenant un antioxydant et procédés d'utilisation
EP4395785A1 (fr) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Méthodes de traitement de la rosacée oculaire
US11357620B1 (en) 2021-09-10 2022-06-14 California LASIK & Eye, Inc. Exchangeable optics and therapeutics
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
WO2023130022A2 (fr) 2021-12-29 2023-07-06 University Of Iowa Research Foundation Compositions d'arn de cystatine pour l'ingénierie tissulaire
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
WO2023164727A1 (fr) 2022-02-28 2023-08-31 University Of Iowa Research Foundation Anticorps anti-a-fabp pour le diagnostic et le traitement de maladies associées à l'obésité
US20230346862A1 (en) 2022-05-02 2023-11-02 Athanor Biosciences, Inc. Cancer eradicating - bio-nanoparticles (ce-bnp)
WO2023215560A1 (fr) 2022-05-05 2023-11-09 Atoosa Corporation Dispositif de mise en prise de récepteur multivalent de cellule tumorale/cellule immunitaire-bio-nanoparticule (timre-bnp)
WO2024037982A1 (fr) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Formulations pharmaceutiques de nintédanib pour utilisation intraoculaire

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3896819A (en) * 1969-04-01 1975-07-29 Alejandro Zaffaroni IUD having a replenishing drug reservoir
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3618604A (en) * 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3632739A (en) * 1969-12-29 1972-01-04 Sandoz Ag Solid sustained release pharmaceutical preparation
US3980463A (en) * 1970-11-16 1976-09-14 Sumitomo Chemical Company, Limited Process for producing granular composition for use in agriculture and horticulture
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US4036227A (en) * 1973-04-25 1977-07-19 Alza Corporation Osmotic releasing device having a plurality of release rate patterns
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3961628A (en) * 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US4142526A (en) * 1974-12-23 1979-03-06 Alza Corporation Osmotic releasing system with means for changing release therefrom
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4247498A (en) * 1976-08-30 1981-01-27 Akzona Incorporated Methods for making microporous products
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4519909A (en) * 1977-07-11 1985-05-28 Akzona Incorporated Microporous products
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
US4290426A (en) * 1978-05-04 1981-09-22 Alza Corporation Dispenser for dispensing beneficial agent
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4730013A (en) * 1981-10-08 1988-03-08 Merck & Co., Inc. Biosoluble ocular insert
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4475916A (en) * 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
DK90883A (da) * 1982-03-18 1983-09-19 Merck & Co Inc Beholder til osmotisk afgivelse af et stof eller en stofblanding
US4432965A (en) * 1982-07-09 1984-02-21 Key Pharmaceuticals, Inc. Quinidine sustained release dosage formulation
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4777049A (en) * 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
EP0147780A3 (fr) * 1984-01-03 1987-03-11 Merck & Co. Inc. Dispositif pour la libération d'un médicament
IT1206166B (it) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
US4692336A (en) * 1984-03-19 1987-09-08 Alza Corporation Self controlled release device for administering beneficial agent to recipient
US4716031A (en) * 1984-03-21 1987-12-29 Alza Corporation Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
US4657543A (en) * 1984-07-23 1987-04-14 Massachusetts Institute Of Technology Ultrasonically modulated polymeric devices for delivering compositions
US4927687A (en) * 1984-10-01 1990-05-22 Biotek, Inc. Sustained release transdermal drug delivery composition
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
US4609374A (en) * 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4717567A (en) * 1985-11-25 1988-01-05 Eastman Kodak Company Rumen-stable pellets
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US5141752A (en) * 1986-05-09 1992-08-25 Alza Corporation Delayed drug delivery device
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4786500A (en) * 1986-06-26 1988-11-22 Alza Corporation Programmable agent delivery system
JPH0794384B2 (ja) * 1986-09-01 1995-10-11 帝国製薬株式会社 徐放性口腔内用製剤
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
IT1223150B (it) * 1987-11-18 1990-09-12 Ubaldo Conte Compressa per uso oftalmico e rilascio controllato della sostanza attiva
US4877618A (en) * 1988-03-18 1989-10-31 Reed Jr Fred D Transdermal drug delivery device
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US4882150A (en) * 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
AU651084B2 (en) * 1990-01-30 1994-07-14 Akzo N.V. Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
IS3778A7 (is) * 1990-10-31 1992-05-02 Amgen Inc. Aðferð til að gefa dýrum vaxtarhormón, þar sem gefnu magni er stýrt

Also Published As

Publication number Publication date
ATE511832T1 (de) 2011-06-15
CA2104699C (fr) 2008-02-12
EP0861659B1 (fr) 2011-06-08
CA2104699A1 (fr) 1992-08-22
DE69227187D1 (de) 1998-11-05
WO1992014450A1 (fr) 1992-09-03
EP0577646A4 (en) 1994-06-01
EP0577646A1 (fr) 1994-01-12
US5378475A (en) 1995-01-03
DE69227187T2 (de) 1999-06-02
JP3908592B2 (ja) 2007-04-25
EP0577646B1 (fr) 1998-09-30
ATE171617T1 (de) 1998-10-15
ES2366573T3 (es) 2011-10-21
ES2125259T3 (es) 1999-03-01
DK0861659T3 (da) 2011-08-29
JPH06505274A (ja) 1994-06-16
JP2003002825A (ja) 2003-01-08
AU660012B2 (en) 1995-06-08
AU1419792A (en) 1992-09-15
EP0861659A1 (fr) 1998-09-02

Similar Documents

Publication Publication Date Title
DK0577646T3 (da) Lægemiddelafgivelsesindretning til forlænget afgivelse
YU11100A (sh) Sistemi koji obezbeđuju podržano oslobađanje leka
CA2230947A1 (fr) Dispositif implantable a liberation regulee pour l'administration de medicaments directement dans une partie interne du corps
DK156289A (da) Farmaceutisk praeparat indrettet til kontrolleret afgivelse af aktiv bestanddel
HK1053263A1 (en) Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
DE69431089D1 (de) Formulierungen mit kontrollierter Abgabe überzogen mit wässrigen Dispersionen von Ethylcellulose
GB2222948B (en) Controlled release device with an impermeable coating having an orifice for release of drug
DE3865631D1 (de) Darreichungsform mit kontrollierter freigabe.
ATE433318T1 (de) Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
NZ313984A (en) Transcorneal drug-release system with multiple microblades and pump
YU48229B (sh) Postupak za izradu flastera kao transdermalnog terapijskog sistema za dirigovano, stupnjevito davanje aktivnih materija preko kože
GEP19991819B (en) Method for Production of Therapeutic Form of Carbamazepin with Retarded Active Substance Release
YU71293A (sh) Transdermalni terapijski sistem za davanje fizostigmina na koži i postupak za njegovu izradu
HUT43959A (en) Medical plasters containing non-continous adhesive layer suitable for getting in therapeutic active agents into skin or through the skin into organism